Connect Biopharma (CNTB) Stock Price, News & Analysis

+0.06 (+3.49%)
(As of 05/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
52,553 shs
Average Volume
79,044 shs
Market Capitalization
$98.08 million
P/E Ratio
Dividend Yield
Price Target

Connect Biopharma MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
265.2% Upside
$6.50 Price Target
Short Interest
0.06% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth
From $0.54 to ($0.63) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.50 out of 5 stars

Medical Sector

297th out of 921 stocks

Pharmaceutical Preparations Industry

126th out of 418 stocks

CNTB stock logo

About Connect Biopharma Stock (NASDAQ:CNTB)

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is CBP-201, an antibody to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis (AD) and asthma. The company's product candidates also comprise CBP-307, a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis; and CBP-174, a peripherally acting antagonist of histamine receptor 3 in development for the treatment of pruritus associated with skin inflammation. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.

CNTB Stock Price History

CNTB Stock News Headlines

Connect Biopharma Holdings Limited (CNTB)
ADRs Advance; Connect Biopharma Climbs 19%
ADRs End Higher; Connect Biopharma Climbs 26%
CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd ADR CNTB
See More Headlines
Receive CNTB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Connect Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$1.83 per share


Free Float
Market Cap
$98.08 million
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Wubin Pan M.B.A. (Age 59)
    Ph.D., Co-Founder, President & Chairman of the Board of Directors
  • Dr. Zheng Wei Ph.D. (Age 60)
    Co-Founder, CEO & Director
  • Mr. Steven Chan (Age 52)
    Chief Financial Officer
  • Mr. Jiang Bian J.D.
    General Counsel & Chief Compliance Officer
  • Dr. Lei Sun Ph.D. (Age 60)
    VP of Biologics & Head of CMC
  • Dr. Raul Collazo Ph.D.
    VP & Global Head of Medical Affairs
  • Dr. Malinda V. Longphre Ph.D.
    VP & Head of US Clinical Operations

CNTB Stock Analysis - Frequently Asked Questions

Should I buy or sell Connect Biopharma stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Connect Biopharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CNTB shares.
View CNTB analyst ratings
or view top-rated stocks.

What is Connect Biopharma's stock price target for 2024?

2 Wall Street research analysts have issued 1 year price targets for Connect Biopharma's shares. Their CNTB share price targets range from $5.00 to $8.00. On average, they predict the company's share price to reach $6.50 in the next twelve months. This suggests a possible upside of 265.2% from the stock's current price.
View analysts price targets for CNTB
or view top-rated stocks among Wall Street analysts.

How have CNTB shares performed in 2024?

Connect Biopharma's stock was trading at $1.18 at the beginning of the year. Since then, CNTB stock has increased by 50.8% and is now trading at $1.78.
View the best growth stocks for 2024 here

When did Connect Biopharma IPO?

Connect Biopharma (CNTB) raised $150 million in an initial public offering on Friday, March 19th 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. Jefferies, VB Leerink, Piper Sandler and CICC served as the underwriters for the IPO.

Who are Connect Biopharma's major shareholders?

Connect Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Keudell Morrison Wealth Management (0.04%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Connect Biopharma?

Shares of CNTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CNTB) was last updated on 5/19/2024 by Staff

From Our Partners